0000000000374511

AUTHOR

Beatriz González

showing 7 related works from this author

Lung ultrasound in outpatients with heart failure: the wet‐to‐dry HF study

2021

The Nancy team is supported by the RHU Fight-HF, a public grant overseen by the French National Research Agency (ANR) as part of the second 'Investissements d'Avenir' programme (reference: ANR-15-RHUS-0004), by the French PIA project 'Lorraine Université d'Excellence' (reference: ANR-15-IDEX-04-LUE), the ANR FOCUS-MR (reference: ANR-15-CE14-0032-01), ERA-CVD EXPERT (reference: ANR-16-ECVD-0002-02), the Contrat de Plan Etat Lorraine IT2MP, and FEDER Lorraine. Aims: In ambulatory patients with chronic heart failure (HF), congestion and decongestion assessment may be challenging. The aim of this study is to assess the value of lung ultrasound (LUS) in outpatients with HF in characterizing deco…

Malemedicine.medical_specialtyHeart failure030204 cardiovascular system & hematologyPulmonary congestion03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicineOutpatientsmedicineHumansDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineLungUltrasonographyHeart FailureLung ultrasoundbusiness.industryHazard ratioOriginal ArticlesPrognosismedicine.diseaseConfidence interval[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthLung ultrasoundRC666-701Heart failureAmbulatoryCardiologyOriginal ArticleFemaleCardiology and Cardiovascular MedicinebusinessAfter treatmentESC Heart Failure
researchProduct

The yeast Starmerella bacillaris (synonym Candida zemplinina) shows high genetic diversity in winemaking environments.

2015

International audience; The yeast Candida zemplinina (Starmerella bacillaris) is frequently isolated from grape and wine environments. Its enological use in mixed fermentation with Saccharomyces cerevisiae has been extensively investigated these last few years, and several interesting features including low ethanol production, fructophily, glycerol and other metabolites production, have been described. In addition, molecular tools allowing the characterization of yeast populations have been developed, both at the inter- and intraspecific levels. However, most of these fingerprinting methods are not compatible with population genetics or ecological studies. In this work, we developed 10 micr…

GlycerolStarmerella bacillaris microsatellite SSR oenology grape mustmicrosatelliteGenotypeGenotyping Techniques[SDV]Life Sciences [q-bio]Saccharomyces cerevisiaePopulation geneticsWineFructoseSaccharomyces cerevisiaestarmerella bacillarisApplied Microbiology and BiotechnologyMicrobiology[SDV.IDA]Life Sciences [q-bio]/Food engineeringBotanymust[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringVitisSelection GeneticDNA FungalWinemakingOenologyCandidaWineGenetic diversitybiologyBase SequenceEthanolGeographyGenetic VariationGeneral MedicineSequence Analysis DNAgrapebiology.organism_classificationSSRYeastCandida zemplininaFermentationoenologyGenome FungalMicrosatellite Repeats
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes.

2021

Abstract Background Treatment resistant depression (TRD) characterizes a subgroup of 10–30% of patients with major depressive disorder, and is associated with considerable morbidity and mortality. A consensus treatment for TRD does not exist, which often leads to wide variations in treatment strategies. Real-world studies on treatment patterns and outcomes in TRD patients in Europe are lacking and could help elucidate current treatment strategies and their efficacy. Methods This non-interventional cohort study of patients with TRD (defined as treatment failure on ≥2 oral antidepressants given at adequate dose and duration) with moderate to severe depression collected real-world data on trea…

Moderate to severemedicine.medical_specialtyMEDLINEAntidepressive Agents; Cohort Studies; Europe; Humans; Depressive Disorder Major; Depressive Disorder Treatment-ResistantReal world evidenceTreatment failureCohort Studies03 medical and health sciencesDepressive Disorder Treatment-Resistant0302 clinical medicineInternal medicinemedicineHumansPsiquiatriaDepression (differential diagnoses)Depressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajormedicine.diseaseAntidepressive Agents030227 psychiatryEuropePsychiatry and Mental healthClinical PsychologyMajor depressive disorderbusinessTreatment-resistant depression030217 neurology & neurosurgeryCohort studyJournal of affective disorders
researchProduct

A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score

2019

Sudden cardiac death (SCD) is one of the main modes of death in heart failure (HF) patients and its prediction remains a real challenge. Our aim was to assess the incidence of SCD at 5 years HF contemporary managed outpatients, and to find a simple prediction model for SCD.SCD was considered any unexpected death, witnessed or not, occurring in a previously stable patient with no evidence of worsening HF or any other cause of death. A competing risk strategy was adopted using the Fine-Gray method of Cox regressions analyses that considered other causes of death as the competing event.The derivation cohort included 744 consecutive outpatients (72% men, age 67.9 ± 12.2 years, left ventricular …

Malemedicine.medical_specialty030204 cardiovascular system & hematologySudden deathSudden cardiac deathCohort Studies03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineAmbulatory CaremedicineHumanscardiovascular diseases030212 general & internal medicineAgedCause of deathAged 80 and overHeart FailureUnivariate analysisEjection fractionTroponin Tbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseDeath Sudden CardiacHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Head-to-head comparison of contemporary heart failure risk scores.

2021

Altres ajuts: acords transformatius de la UAB Aims: Several heart failure (HF) web-based risk scores are currently used in clinical practice. Currently, we lack head-to-head comparison of the accuracy of risk scores. This study aimed to assess correlation and mortality prediction performance of Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC-HF) risk score, which includes clinical variables + medications; Seattle Heart Failure Model (SHFM), which includes clinical variables + treatments + analytes; PARADIGM Risk of Events and Death in the Contemporary Treatment of Heart Failure (PREDICT-HF) and Barcelona Bio-Heart Failure (BCN-Bio-HF) risk calculator, which also include biomarke…

medicine.medical_specialtyCalibration (statistics)Head to headHeart failureSpearman's rank correlation coefficientRisk AssessmentCorrelationRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineRisk modelsHumansOverall performanceMortalityNatriuretic PeptidesHeart FailureFramingham Risk Scorebusiness.industrymedicine.diseasePrognosisRisk predictionPeptide FragmentsClinical PracticeHeart failureCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean journal of heart failureReferences
researchProduct

Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise.

2019

AIMS Better management of heart failure (HF) over the past two decades has improved survival, mainly by reducing the incidence of death due to cardiovascular (CV) causes. Deaths due to non-CV causes, particularly cancer, may be increasing. This study explored the modes of death of consecutive patients who attended a HF clinic over 17 years. METHODS AND RESULTS A total of 935 deaths were ascertained from 2002 to 2018 among 1876 patients (mean age 65.8 ± 12.5 years, 75% men, left ventricular ejection fraction < 50%) admitted to our HF clinic. Median follow-up was 4.2 years [1.9-7.8]. Mode of death was curated from patient health records and verified by the Catalan and Spanish health system da…

MalePediatricsmedicine.medical_specialtyManagement of heart failure030204 cardiovascular system & hematologyHealth recordsSudden death03 medical and health sciencesDeath Sudden0302 clinical medicineNeoplasmsmedicineHumansLongitudinal StudiesMortalityLung cancerAgedHeart FailureEjection fractionbusiness.industryIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseSpainHeart failureFemaleCardiology and Cardiovascular MedicinebusinessEuropean journal of heart failureReferences
researchProduct

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction.

2018

Objective: To assess the effects of comorbidities, fragility, and quality of life (QOL) on long-term prognosis in ambulatory patients with heart failure (HF) with midrange left ventricular ejection fraction (HFmrEF), an unexplored area. Patients and Methods: Consecutive patients prospectively evaluated at an HF clinic between August 1, 2001, and December 31, 2015, were retrospectively analyzed on the basis of left ventricular ejection fraction category. We compared patients with HFmrEF (n=185) to those with reduced (HFrEF; n=1058) and preserved (HFpEF; n=162) ejection fraction. Fragility was defined as 1 or more abnormal evaluations on 4 standardized geriatric scales (Barthel Index, Older A…

medicine.medical_specialtylcsh:R5-920Ejection fractionbusiness.industryDepression scaleComorbidity score030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineFragilityQuality of lifeHeart failureInternal medicineAmbulatoryCardiologyMedicineGeriatric Depression Scale030212 general & internal medicinebusinesslcsh:Medicine (General)Mayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct